45583503 PET/CT | Cancer Diagnostic - ¹⁷⁷Lu-PSMA Prostate Cancer Therapy

+371 27-078-822|| |

ENROLL FOR CLINIC SERVICE

ENROLL OR ASK FOR PRICE

Innovative and Effective Treatment
for Metastatic Prostate Cancer

WHAT IS LUTETIUM THERAPY (177Lu-PSMA)?

The treatment with radioactive isotope 177Lu-PSMA is an effective treatment method for metastatic prostate cancer. 177Lu-PSMA therapy is used when treatment options with other approved methods have been exhausted, have proven ineffective, or the patient cannot tolerate them. The aim of the 177Lu-PSMA therapy is to reduce tumor volume, the rate of metastatic dissemination and other symptoms of the disease. "RSU Nuclear Medicine Clinic" is one of the few medical centers in the world that offers such an innovative treatment method.

WHAT IS THE EFFECT OF 177Lu-PSMA THERAPY?

The amount of prostate-specific membrane antigen (PSMA) increases significantly in prostate cancer cells, and if the prostate cancer has spread to other parts of the body, then PSMA expression will be detectable there, too. 177Lu-PSMA binds to PSMA receptors found on cancer cells, and radioactive isotope 177Lu destroys these cancer cells.

177 Lu-PSMA THERAPY PROCEDURE DETAILS

  • 177Lu-PSMA therapy is done as an outpatient procedure in the RSU Nuclear Medicine Clinic.
  • 177Lu-PSMA is administered through a peripheral venous catheter.
  • One treatment session lasts 6-8 hours, during which time the patient must remain in the clinic.
  • The total treatment consists of 2-6 cycles with 6-8 week intervals.
  • Close and prolonged contact with people should be avoided 24 hours after the injection (it is advisable to refrain from flying/traveling/attending events).

FREQUENTLY OBSERVED ADVERSE REACTIONS:

The majority of patients treated with 177Lu-PSMA do not experience serious adverse reactions. The most frequent are:

  • Dry mouth and/or eyes (up to 30% of patients).
  • Nausea and vomiting (up to 10% of patients).
  • Haematopoietic suppression in patients with metastatic bone lesions.

PATIENT SELECTION CRITERIA:

INCLUSION CRITERIA:

  1. Patients with metastatic castration-resistant prostate cancer (mCRPC) for whom the available approved (alternative) treatment methods have been exhausted or are not suitable.
  2. Patients who have previously undergone the following examinations:
    • PET/CT with PSMA, not earlier than 2 months before the 177Lu-PSMA therapy, which confirms the increased PSMA expression.
    • A complete blood count with serum biochemistry, including ASAT, ALT, creatinine, PSA level in the serum, not earlier than 10 days prior to 177Lu-PSMA therapy.
  3. Information about the stage of the disease before the treatment, information about the treatments applied, previous examinations, histological results.
  4. The patient agrees to the use of anonymized data for research purposes.
  5. The decision on the appropriateness of 177Lu-PSMA therapy for each specific patient is made by the consortium of specialist doctors.

EXCLUSION CRITERIA:

  1. General health status according to the Karnofsky > 70 points, unless the aim of the therapy is to reduce symptoms of the disease.
  2. Severe dysfunction of the urinary system (obstruction, hydronephrosis).
  3. Advancing and uncontrolled illnesses, including liver and kidney diseases, and infections.
  4. Suppression of the bone marrow function:
    • leukocyte count < 2.5 x 109/L
    • thrombocyte count < 75 x 109/L

FEEL FREE TO

Contact Us

If you have any questions please feel free to contact our customer support centre.
Our specialist will answer you as soon as possible, but not longer than 24 hours (on working days).

medvision logotype
© Rīga Stradiņš University Nuclear Medicine Clinic